Pipeline

先进的药物，既表现出强大的临床表现，又对患者有益.

Pipeline
90
+
compounds, 单独或合作或许可协议开发的设备或适应症
investment
$6.4
b
R&D 2022年投资
Commitment
50
+
项目已进入中后期开发阶段
Novel
80
%
具有新的作用机制的化合物的临床开发

Pipeline

2023年3月10日更新

Sort By 
Focus Area
分子/资产阶段
分子/资产类型
设备资产阶段
Device Asset Type
AGN-241622
Small Molecule Pharmaceutical Eye Care 阿尔法2肾上腺素能受体
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Presbyopia
N ∕ A
N ∕ A phase1
phase1
AL002
TREM 2 Biologic Pharmaceutical Neuroscience Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
TTX-030
Biologic Pharmaceutical Oncology CD39 Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-383
CD3-BCMA Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
QULIPTA™
Small Molecule Pharmaceutical CGRP Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
慢性偏头痛预防
US , EU
US , EU submitted
submitted
发作性偏头痛预防
US EU
US approved
EU submitted
approved
submitted
ABBV-400
Biologic c-Met Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-151
Biologic GARP-TGF-β1 Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
AGN-231868
Small Molecule Pharmaceutical Eye Care Chemokines
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Dry Eye
N ∕ A
N ∕ A phase2
phase2
BOTOX®
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阔肌突出
N ∕ A
N ∕ A phase3
phase3
咬肌突出
N ∕ A
N ∕ A phase3
phase3
ABBV-368
Biologic Pharmaceutical Oncology anti-OX40
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-CX-2029
Biologic CD-71 Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
实体和血液肿瘤
N ∕ A
N ∕ A phase2
phase2
Armour Thyroid
Large Molecule Pharmaceutical T3T4 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Hypothyroidism
N ∕ A
N ∕ A phase2
phase2
Telisotuzumab vedotin
Biologic c-Met Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
非小细胞肺癌
N ∕ A
N ∕ A phase3
phase3
HPN-217
CD3-BCMA Biologic Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
多发性骨髓瘤复发
N ∕ A
N ∕ A phase1
phase1
OnabotA X
Large Molecule Pharmaceutical SNARE Proteins Aesthetics Combination
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Glabellar Lines
N ∕ A
N ∕ A phase2
phase2
Forehead Lines
N ∕ A
N ∕ A phase2
phase2
ABBV-CLS-579
PTPN2 Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-647
Biologic Pharmaceutical Oncology PTK7
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-744
BET BDII Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Myelofibrosis
N ∕ A
N ∕ A phase1
phase1
AGN-242428
RORg Small Molecule Pharmaceutical Eye Care
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Dry Eye
N ∕ A
N ∕ A phase2
phase2
ABBV-951
Dopamine Receptor Small Molecule Pharmaceutical Neuroscience Combination
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
帕金森病
US
US submitted
submitted
Imbruvica
BTK Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
滤泡淋巴瘤
US , EU
US , EU phase3
phase3
套细胞淋巴瘤
N ∕ A
N ∕ A phase3
phase3
ABBV-CLS-7262
eIF2B Small Molecule Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
肌萎缩性侧索硬化症(ALS)
N ∕ A
N ∕ A phase1
phase1
BOTOX®
Large Molecule Pharmaceutical Neuroscience SNARE Proteins
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
发作性偏头痛预防
N ∕ A
N ∕ A phase3
phase3
Essential Tremor
N ∕ A
N ∕ A phase2
phase2
ABBV-599
BTK Immunology Small Molecule JAK1 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase2
phase2
ABBV-154
Biologic Immunology TNF Pharmaceutical Combination
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Crohn's Disease
N ∕ A
N ∕ A phase2
phase2
风湿性多肌痛
N ∕ A
N ∕ A phase2
phase2
CLBR001 + SWI019
Biologic Pharmaceutical Oncology Partner Asset CD19
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
BOTOX®
Large Molecule Pharmaceutical SNARE Proteins 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
IC BPS
N ∕ A
N ∕ A phase2
phase2
SKYRIZI®
Biologic Immunology IL-23 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Crohn's Disease
US , EU
US , EU approved
approved
Psoriasis
US , EU
US , EU approved
approved
银屑病关节炎
US , EU
US , EU approved
approved
溃疡性结肠炎
N ∕ A
N ∕ A phase3
phase3
ABBV-181
Biologic Pharmaceutical anti-PD1 Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
BoNTE
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Glabellar Lines
N ∕ A
N ∕ A phase3
phase3
AGN-151607
SNAP25 Biologic Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
术后房颤
Global
Global phase2
phase2
ABBV-CLS-484
PTPN2 Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
JAB-3312
SHP2 Small Molecule Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
美国、欧盟、亚洲(不包括. China)
美国、欧盟、亚洲(不包括. China) phase1
phase1
阿曲南/阿维巴坦
Small Molecule Pharmaceutical PBP3 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
复杂革兰氏阴性感染
N ∕ A
N ∕ A phase3
phase3
ABBV-514
Biologic Pharmaceutical Oncology N A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ALPN-101
Biologic 双CD28-ICOS拮抗剂 Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
系统性红斑狼疮(SLE)
Global
Global phase2
phase2
ABBV-637
Biologic EGFR Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
CF Combo
CFTR-C2 Small Molecule CFTR-C1 CFTR-P Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Cystic Fibrosis
N ∕ A
N ∕ A phase2
phase2
ABBV-927
anti-CD40 Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Elezanumab (abt - 555)
Biologic RGMa Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
脊髓损伤
N ∕ A
N ∕ A phase2
phase2
急性缺血性中风
N ∕ A
N ∕ A phase2
phase2
Veliparib
PARP Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Breast Cancer
N ∕ A
N ∕ A phase3
phase3
Ovarian Cancer
N ∕ A
N ∕ A phase3
phase3
ABBV-552
Small Molecule Pharmaceutical Neuroscience SV2A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阿尔茨海默病
N ∕ A
N ∕ A phase1
phase1
ABBV-011
Biologic Pharmaceutical Oncology N A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
小细胞肺癌
N ∕ A
N ∕ A phase1
phase1
ABBV-706
Biologic Pharmaceutical SEZ6 ADC Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
小细胞肺癌
N ∕ A
N ∕ A phase1
phase1
CUG-252
IL-2 Mutein Biologic Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase1
phase1
ABBV-903
Mpro Inhibitor Small Molecule Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
COVID
N ∕ A
N ∕ A phase1
phase1
ABBV-525
Small Molecule Pharmaceutical MALT1 Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
ABBV-319
Biologic C19∕Steriod ADC Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
AGN-193408
Intracameral植入 Pharmaceutical Eye Care PGF2受体
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
开角型青光眼
N ∕ A
N ∕ A phase2
phase2
Occular高血压
N ∕ A
N ∕ A phase2
phase2
ABBV-453
Small Molecule Pharmaceutical Oncology Bcl-2
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
复发性∕难治性多发性骨髓瘤
N ∕ A
N ∕ A phase1
phase1
CLF065
GLP-2 agonist Biologic Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
IBD
N ∕ A
N ∕ A phase1
phase1
Eftoza
Biologic Pharmaceutical Oncology Trail Agonist
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
实体和血液肿瘤
N ∕ A
N ∕ A phase1
phase1
ABBV-155
Biologic Pharmaceutical Oncology N A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
实体和血液肿瘤
N ∕ A
N ∕ A phase1
phase1
RINVOQ™
Immunology Small Molecule JAK1 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
强直性脊柱炎
US , EU
US , EU approved
approved
Atopic Dermatitis
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US EU
US submitted
EU submitted
submitted
submitted
巨细胞动脉炎
US , EU
US , EU phase3
phase3
位患化脓性汗腺炎
N ∕ A
N ∕ A phase2
phase2
银屑病关节炎
US , EU
US , EU approved
approved
类风湿性关节炎
US , EU
US , EU approved
approved
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase2
phase2
Takayasu指出动脉炎
JA
JA phase3
phase3
溃疡性结肠炎
US , EU
US , EU approved
approved
Vitiligo
N ∕ A
N ∕ A phase2
phase2
Venclexta™
Small Molecule Pharmaceutical Oncology Bcl-2
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
急性淋巴细胞白血病
N ∕ A
N ∕ A phase1
phase1
急性髓系白血病
US , EU
US , EU approved
approved
移植后急性髓系白血病
N ∕ A
N ∕ A phase3
phase3
慢性淋巴细胞白血病，缺失17p
US , EU
US , EU approved
approved
一线慢性淋巴细胞白血病
US , EU
US , EU approved
approved
骨髓增生异常综合征
US , EU
US , EU phase3
phase3
Multiple Myeloma
N ∕ A
N ∕ A phase3
phase3
复发/难治性慢性淋巴细胞白血病
US , EU
US , EU approved
approved
ABBV-668
Immunology RIPK1 Small Molecule Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
溃疡性结肠炎
N ∕ A
N ∕ A phase2
phase2
Lutikizumab
Biologic Immunology Pharmaceutical IL-1a ∕ 1b
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
位患化脓性汗腺炎
N ∕ A
N ∕ A phase2
phase2
Vraylar
5-HT2A拮抗剂 Small Molecule Pharmaceutical 多巴胺D2部分激动剂 Neuroscience 5-HT1A部分激动剂
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Adjunctive MDD
US
US approved
approved
Epcoritamab
Biologic DuoBody-CD3xCD20 Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
一线大b细胞淋巴瘤
US , EU
US , EU phase3
phase3
复发∕难治性滤泡性淋巴瘤
N ∕ A
N ∕ A phase3
phase3
b细胞非霍奇金淋巴瘤
N ∕ A
N ∕ A phase2
phase2
复发/难治性慢性淋巴细胞白血病
N ∕ A
N ∕ A phase1
phase1
里希特氏综合征
N ∕ A
N ∕ A phase1
phase1
RGX-314
Biologic Pharmaceutical Eye Care Partner Asset VEGF
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
湿性AMD(视网膜下)
N ∕ A
N ∕ A phase3
phase3
湿性AMD(脉络膜上)
N ∕ A
N ∕ A phase2
phase2
糖尿病性视网膜病变(脉络膜上)
N ∕ A
N ∕ A phase2
phase2
ABBV-916
Biologic AßpE3 Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
ABBV-1882
抗pd1和抗a4b7单抗 Biologic Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
HIV
N ∕ A
N ∕ A phase1
phase1
ABBV-4083
Wolbachia Small Molecule Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Filarial Diseases
N ∕ A
N ∕ A phase2
phase2
Resonic
Body Contouring Device Cellulite Aesthetics
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
Cellulite
N A
N A confirmation
confirmation
Juvederm®voluma®xc
面部美学 Device Aesthetics 下巴增大 Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
下巴增大
US
US confirmation
confirmation
Juvederm®volite®xc
面部美学 Device Skin Deformities Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
细纹减少
US , EU , JA
US , EU , JA confirmation
confirmation
Juvederm®volux®xc
面部美学 Device 下颌的轮廓定义 Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
下颌的轮廓定义
US
US confirmation
confirmation
HArmonyCa™
面部美学 Device 面部轮廓 Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
Facial Volume
N A
N A confirmation
confirmation
Tropoelastin
面部美学 Device Skin Deformities Aesthetics
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
Atrophic Scars
N A
N A confirmation
confirmation
Juvederm®volbella®xc
面部美学 Device Aesthetics Combination 眼眶下的挖空
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
眼眶下的挖空
US
US confirmation
confirmation
No Results Found 更改筛选器或搜索条件.
Popular pages
External links

除非另有说明, 本网站出现的所有产品名称均为AbbVie Inc .拥有或授权给AbbVie Inc .的商标.、其附属公司或联属公司. 不使用任何澳门顶级网赌网址大全商标, trade name, 在未经澳门顶级网赌网址大全公司事先书面授权的情况下，可以在本网站上制作或商业外观.，但用于识别澳门顶级网赌网址大全或服务的除外.

版权所有©2023澳门顶级网赌网址大全公司. 北芝加哥，伊利诺伊州，美国.S.A.